Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06803680 · ClinicalTrials.gov registry record · Phase 1

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by BeiGene.

Recruiting
Registry status
Phase 1
Development phase
90
Enrollment target
13
Study locations

NCT06803680: Recruiting Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by BeiGene.

NCT06803680 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor that is actively recruiting participants, run by BeiGene. The registered enrollment target is 90 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (53% lower). The trial reports 13 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06803680, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, is actively recruiting participants, sponsored by BeiGene.

RECRUITING
Registry status
Phase 1
Development phase
90 participants
Enrollment target
13
Study locations

Study Summary

The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participants have when taking BGB-B455? The study has two parts: * Phase 1a: dose escalation and safety expansion * Phase 1b: dose expansion

Primary Outcome

Number of participants with AEs and SAEs, including laboratory abnormalities, and AEs that meet protocol-defined dose-limiting toxicity (DLT) criteria or protocol-defined adverse events of special interest (AESI) criteria.

Conditions Studied

Advanced Solid Tumor Metastatic Solid Tumor

Interventions

  • DRUG Chemotherapy
  • DRUG BGB-B455

Study Locations (13)

New South Wales

  • Blacktown Cancer and Haematology Centre - Blacktown
  • Liverpool Hospital - Liverpool

Florida

  • Adventhealth - Celebration

Pennsylvania

  • Sidney Kimmel Cancer Center - Philadelphia

South Dakota

  • Avera Cancer Institute - Sioux Falls

Texas

  • Next Oncology - San Antonio

Washington

  • Fred Hutchinson Cancer Research Center - Seattle

Queensland

  • Mater Cancer Care Centre - South Brisbane

Beijing Municipality

  • Beijing Cancer Hospital - Beijing

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-03-18
Est. Completion 2027-10-30
Phase Phase 1
BeiGene

65 total trials

What NCT06803680 shows while recruiting

NCT06803680 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (53% lower).

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy is the first listed.

NCT06803680 lists 13 locations in 12 states (New South Wales, Florida, Pennsylvania).

Frequently Asked Questions

What is clinical trial NCT06803680 about?

NCT06803680 is a clinical study titled "A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors". The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participan...

What is the current status of trial NCT06803680?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2025-03-18. Estimated completion is 2027-10-30.

What conditions does trial NCT06803680 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumor.

What interventions are being tested in trial NCT06803680?

The interventions under investigation include: Chemotherapy (DRUG), BGB-B455 (DRUG).

Who is sponsoring clinical trial NCT06803680?

This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06803680 being conducted?

This trial has 13 study locations across Florida, Pennsylvania, South Dakota, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06803680's enrollment target sits among peer trials

90 123rd of 189 higher than 63 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06803680

Source: ClinicalTrials.gov NCT06803680, the US trial registry maintained by the National Library of Medicine. NCT06803680 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.